While taking into consideration the potential modulation of Gal-3 for the prevention of myocardial fibrosis, one study and two randomized controlled trials (RCTs) assessed the effect of an aldosterone antagonist agent, eplerenone, and a prostacyclin analogue, iloprost, on its circulating levels [98,99,100], while, in one RCT, eplerenone did not significantly influence the Gal-3 levels in adults with a childhood diagnosis of ToF or complete TGA. The gene discussed is LGALS3; the disease is Myocardial fibrosis.